WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported ...
Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...
Zacks.com on MSN1d
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY GainsAbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...
AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...
Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.
1d
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
For AbbVie, the failure of a high-profile schizophrenia drug hardly marks its last chance to invest in neuroscience. But the ...
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a ...
In commodity markets, Brent crude oil was down 2.6% to US$71.94 a barrel, while gold was down 2.4% to US$2,621.17. The ...
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback